The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| AXIM | +66.53% | -98.31% | -55.78% | -86% |
| S&P | +18.33% | +108.18% | +15.79% | +316% |
AXIM Biotechnologies, Inc. operates as a biotechnology company, which engages in the development of diagnostic healthcare solutions. Its product categories include Eye Health, SARS-CoV-2, and fentanyl neutralizing antibody test. The company was founded on November 18, 2010 and is headquartered in San Diego, CA.
These pot stocks are bad news for investors.
Whether it's a single-drug portfolio or little cash on hand, these drug developers are the definition of risk.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | -100.0% |
| Gross Profit | -$0.11M | -17.0% |
| Gross Margin | -528.60% | 0.0% |
| Market Cap | $1.82M | -37.0% |
| Market Cap / Employee | $0.26M | 0.0% |
| Employees | 7 | 0.0% |
| Net Income | $0.14M | 106.0% |
| EBITDA | -$0.18M | 60.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $0.00M | -53.6% |
| Inventory | 0 | -100.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $7.25M | 14.8% |
| Short Term Debt | $0.10M | 9.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -30.17% | 73.5% |
| Return On Invested Capital | -442.88% | -11.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$0.67M | -157.5% |
| Operating Free Cash Flow | -$0.67M | -157.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -0.15 | -0.06 | -0.11 | -0.19 | -49.26% |
| Price to Sales | 30.79 | 18.18 | 8.60 | 71.96 | 104.32% |
| Price to Tangible Book Value | -0.11 | -0.04 | -0.09 | -0.15 | -42.21% |
| Enterprise Value to EBITDA | -27.11 | -27.72 | -50.00 | -51.32 | 155.59% |
| Total Debt | $7.01M | $6.64M | $6.78M | $7.35M | 14.75% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
